Intellectual property, pharmaceutical MNEs and the developing world

The paper examines the structure of pharmaceutical R&D funding, spillovers and public–private-academic research linkages in the developing countries. The paper also examines several policy options aimed at mitigating the trade off between the twin and often conflicting objectives of preserving i...

Full description

Saved in:
Bibliographic Details
Published in:Journal of world business : JWB 2009-04, Vol.44 (2), p.206-215
Main Authors: Ghauri, Pervez N., Rao, P.M.
Format: Article
Language:English
Subjects:
Developing countries
Economic policy
Innovation
Innovation Intellectual property Pharmaceuticals The developing world
Intellectual property
LDCs
Multinational corporations
Multinational enterprises
Pharmaceutical industry
Pharmaceuticals
R&D
Research & development
Research & development expenditures
Research and development
Spillovers
Studies
The developing world
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The paper examines the structure of pharmaceutical R&D funding, spillovers and public–private-academic research linkages in the developing countries. The paper also examines several policy options aimed at mitigating the trade off between the twin and often conflicting objectives of preserving incentives for the multinational enterprise (MNE) innovation and making patented drugs accessible to the poor countries at affordable prices. The paper argues for a vastly expanded size and scope of public-academic-nonprofit funding of R&D, whose results could become a global public good. Finally, the paper suggests that the international business scholars further explore the implications of the strong private–public-academic linkages found in the pharmaceutical research combined with the trends towards open innovation and economic development.
ISSN:1090-9516
1878-5573
DOI:10.1016/j.jwb.2008.05.008